In the United States,<unk>  is indicated for: * Moderate to Severe Rheumatoid Arthritis (RA) (Nov 1998) * Moderate to Severe Polyarticular Juvenile Rheumatoid Arthritis (May 1999) * Psoriatic Arthritis (Jan 2002) * Ankylosing Spondylitis (AS) (July 2003) * Moderate to Severe Plaque Psoriasis (April 2004) In the European Union,<unk>  is indicated to treat: * moderate to severe active rheumatoid arthritis * severe, active and progressive rheumatoid arthritis * juvenile idiopathic arthritis * polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents * active and progressive psoriatic arthritis * enthesitis-related arthritis * axial spondyloarthritis * severe active ankylosing spondylitis * severe non-radiographic axial spondyloarthritis * moderate to severe plaque psoriasis * chronic severe plaque psoriasis pediatric plaque psoriasis
Etanercept
Adalimumab
Tofacitinib
Belatacept
Abatacept
Belimumab
Teriflunomide
Theralizumab